Trends - Pharmaceuticals - Business Recorder

Print

LSM output up 8.16pc in 1HFY21

ISLAMABAD: The overall output of the Large Scale Manufacturing Industries (LSMI) increased by 8.16 percent in the...

Published 13 Feb, 2021 04:11am

Business & Finance

Physician-administered macular degeneration drug Eylea sales were hurt during the height of the pandemic last year as patients were reluctant to visit doctors' offices.
Sales from eczema drug Dupixent, which are recorded by Regeneron partner Sanofi, were $1.17 billion, compared to $751.5 million a year earlier.

Published 05 Feb, 2021 05:53pm

Business & Finance

KARACHI: Faisal Moiz Khan, President North Karachi Association of Trade & Industry (NKATI), has opposed the...

Published 21 Jan, 2021 04:23am

Business & Finance

Pakistan plans on starting mass-production of snakebites anti-venom and a rabies vaccine next year to end its reliance on imports from India.
Dow University of Health Sciences' biotechnological facility will be able to produce 700,000 vials of venom antiserum annually to overcome the supply shortages in the country.

Updated 28 Dec, 2020 07:00pm

Business & Finance

Pakistan plans on starting mass-production of snakebites anti-venom and a rabies vaccine next year to end its reliance on imports from India.
Dow University of Health Sciences' biotechnological facility will be able to produce 700,000 vials of venom antiserum annually to overcome the supply shortages in the country.

Updated 28 Dec, 2020 07:02pm

World

India will deploy its vast election machinery to deliver 600 million doses of COVID-19 vaccines to the most vulnerable people in the next six to eight months through conventional cold chain systems.
Serum Institute of India, the world’s largest vaccine maker, is already mass producing and stockpiling AstraZeneca’s Covishield shot.

Published 12 Dec, 2020 06:22pm